TSE:4577Pharmaceuticals
Daito Pharmaceutical (TSE:4577) Margin Jump In Q3 2026 Tests Long Term Earnings Skepticism
Daito PharmaceuticalLtd (TSE:4577) has put up a clean set of Q3 2026 numbers, with revenue of ¥11.6b and basic EPS of ¥35.41, set against a trailing twelve month EPS of ¥99.48 and net income of ¥3.0b. The company has seen quarterly revenue move from ¥12.0b in Q3 2025 to ¥11.6b in Q3 2026, while basic EPS over that span shifted from ¥10.15 to ¥35.41, presenting a story in which higher margins and earnings growth potential sit at the center of the latest update.
See our full analysis for Daito...